{
  "alleleExist":false,
  "dataVersion":"v4.5",
  "diagnosticImplications":[
    {
      "abstracts":[],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "description":"",
      "levelOfEvidence":"LEVEL_Dx3",
      "pmids":[
        "22237106"
      ],
      "tumorType":{
        "children":{},
        "code":"ETPLL",
        "color":"LimeGreen",
        "id":857,
        "level":4,
        "mainType":{
          "id":null,
          "name":"T-Lymphoblastic Leukemia/Lymphoma",
          "tumorForm":"LIQUID"
        },
        "name":"Early T-Cell Precursor Lymphoblastic Leukemia",
        "parent":"TLL",
        "tissue":"Lymphoid",
        "tumorForm":"LIQUID"
      }
    },
    {
      "abstracts":[],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "description":"",
      "levelOfEvidence":"LEVEL_Dx3",
      "pmids":[
        "21390126"
      ],
      "tumorType":{
        "children":{},
        "code":"FL",
        "color":"LimeGreen",
        "id":286,
        "level":5,
        "mainType":{
          "id":null,
          "name":"Mature B-Cell Neoplasms",
          "tumorForm":"LIQUID"
        },
        "name":"Follicular Lymphoma",
        "parent":"MBN",
        "tissue":"Lymphoid",
        "tumorForm":"LIQUID"
      }
    }
  ],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"EP300, a tumor suppressor and histone acetyltransferase, is inactivated in various cancer types.",
  "highestDiagnosticImplicationLevel":"LEVEL_Dx3",
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":false,
  "lastUpdate":"02/14/2018",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "10700188",
        "12237408",
        "15156177",
        "12402157"
      ]
    },
    "description":"EP300 truncating mutations result in EP300 proteins that lack some (or all) of the key enzymatic domains: the histone acetyltransferase (HAT) domain, the bromodomain and transcription factor binding domains (PMID: 10700188, 15156177, 12402157). Functional studies have shown that deletion of these domains result in decreased acetyltransferase and tumor suppressive activity (PMID: 12237408). These truncations are loss-of-function alterations, highlighted by the finding that truncation of one allele is highly associated with loss of the second EP300 allele (PMID: 10700188). Truncation of EP300 leads to disruption of signaling cascades such as the TGF\u03b2 pathway (PMID: 12237408).",
    "knownEffect":"Likely Loss-of-function"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"Q2164Rfs*5",
    "alterationType":null,
    "consequence":"frameshift_variant",
    "entrezGeneId":2033,
    "hgvs":null,
    "hugoSymbol":"EP300",
    "id":null,
    "proteinEnd":2162,
    "proteinStart":2162,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":false,
  "variantSummary":"The EP300 Q2164Rfs*5 mutation is likely oncogenic.",
  "vus":false
}